In a rodent model of psychosis obtained by the administration of subanaesthetic dose of the N-methyl-d-aspartate (NMDA)-receptor antagonist ketamine, NOX2 has been shown to be a major producer of ROS in the brain, controlling glutamate release and, ultimately, leading to behavioral alterations [6, 7]. This evidence concerns the gene CYBB and psychotic disorder.